Business Context and Reporting Period
This Form 8-K is a current report filed by Catalyst Biosciences, Inc. on April 24, 2017. The filing addresses Item 8.01 (Other Events) regarding the completion of a public offering of securities that occurred on April 12, 2017.
Key Financial Metrics
The filing does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on capital structure updates following the public offering.
- Common Stock Outstanding: 4,260,161 shares (as of April 20, 2017).
- Series A Preferred Stock Outstanding: 5,750 shares (as of April 20, 2017).
- Conversion Rights: Series A Preferred Stock is convertible into an aggregate of 1,150,000 shares of Common Stock.
Material Changes
The primary material change reported is the completion of the public offering on April 12, 2017, which resulted in the capitalization figures noted above as of April 20, 2017. No comparative financial data or prior period metrics are included in this specific filing.
Guidance, Outlook, and Risks
The filing text does not provide management commentary, financial guidance, outlook, specific risks, contingencies, or unusual items beyond the disclosure of the completed offering and current share counts.
Investor Verification Checklist
- Verify the final share count and capitalization table in the company's most recent 10-K or 10-Q to confirm the impact of the April 2017 offering.
- Review the prospectus or offering documents to understand the terms of the Series A Preferred Stock conversion.
- Confirm the use of proceeds from the public offering in subsequent financial reports.